US regulatory status: approved.
pharma · Symptomatic hypertrophic cardiomyopathy (HCM) · SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Cytokinetics
Cytokinetics (Ireland) Limited
Cytokinetics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
South San Francisco, USA HQ
1998 Founded
759 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 1998
- Employees
- 759
- Programs
- 5
- Drugs
- 7
- Patents
- 0
Cytokinetics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cytokinetics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cytokinetics in public FDA and regional records.
-
Development asset linked to Cytokinetics in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
omecamtiv mecarbil
Cardiovascular system (C01)Cardiovascular system (C01) compound in Cytokinetics's portfolio. Molecular target: Cardiac myosin.
- Target
- Cardiac myosin
- Mechanism
- Cardiac myosin activator
-
Development asset linked to Cytokinetics in public FDA and regional records.
-
Development asset linked to Cytokinetics in public FDA and regional records.